Literature DB >> 8485272

The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers.

H G Dammann1, A von zur Mühlen, H J Balks, A Damaschke, J Steinhoff, U Hennig, J A Schwarz, W Fuchs.   

Abstract

Seven days of dosing with either 30 mg or 60 mg of lansoprazole were compared with placebo in a double-blind, randomized, three-way cross-over study in 12 male healthy volunteers. Twenty-four-hour intragastric pH was measured after 7 days of dosing with each regimen, as well as 3 and 7 days after the end of dosing. During dosing with placebo, intragastric pH was above 4 for a median of 51 minutes. pH values were significantly raised to above 4 for 8.45 and 8.33 hours on Day 7 of dosing with lansoprazole 30 and 60 mg, respectively, but returned to normal by the third day after stopping dosing. No clinically relevant influence on endocrine function (serum concentrations of insulin, aldosterone, testosterone, parathormone, glucagon, T3, T4, TSH, LH, FSH, STH, prolactin, circadian cortisol profile, ACTH test) was observed. No serious adverse clinical or laboratory events were noted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485272     DOI: 10.1111/j.1365-2036.1993.tb00089.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Proton-pump inhibition and gastric giardiasis: a causal or casual association?

Authors:  H Reynaert; E Fernandes; C Bourgain; L Smekens; G Devis
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 2.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 3.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 5.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 6.  Medical management of esophageal reflux.

Authors:  B I Hirschowitz
Journal:  Yale J Biol Med       Date:  1994 May-Aug
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.